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The pathogenesis of renal ischemia/reperfusion (I/R) injury
involves activating several signal transduction cascade
systems in endothelial cells. Sphingosine 1-phospate (S1P)
maintains endothelial cell integrity and inhibits lymphocyte
egress via the specific S1P1 receptor, and may play a role in
reducing ischemic renal injury. We examined the protective
effects of a newly identified S1P1-selective agonist, SEW2871,
on mouse renal I/R injury. Kidneys were harvested 1–4 days
after I/R injury for histopathology, immunofluorescence
studies, and quantitative real-time reverse transcriptase-
polymerase chain reaction analyses to assess the change in
gene expression profiles of inflammation-associated
cytokines and adhesion molecules. SEW2871 improved renal
function with a 40% reduction in plasma creatinine levels
(Po0.01) and a significant reduction in tubular necrosis
scores (I/R only: 4.370.2 vs I/Rþ SEW2871: 2.570.4, Po0.05)
24 h after ischemia. These changes were accompanied by
69% reduction in circulating lymphocytes, and 77 and 66%
reduction in infiltrating neutrophils and macrophages in
renal outer medulla, respectively (all Po0.01). The mRNA
abundance of tumor necrotic factor-a (TNF-a), P-selectin,
E-selectin, and intercellular adhesion molecule-1 (ICAM-1)
was markedly increased by I/R injury (3.5-, 4.1-, 3.5-, and
4.8-folds, respectively, all Po0.05 vs sham). SEW2871
treatment partially reversed the upregulation of TNF-a,
P-selectin, and ICAM-1 (47, 59, 54%, respectively, vs I/R
control: 100%, all Po0.05). The reduction in protein
expression of TNF-a, P-selectin, and ICAM-1 was further
confirmed with immunofluorescence studies. These results
suggest that SEW2871 ameliorates renal I/R injury by
inhibiting lymphocyte egress and reducing pro-inflammatory
molecules. This new class of renoprotective agent shows
promise as a novel approach in preventing/treating ischemic
acute renal failure.
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The pathogenetic mechanisms of ischemia and reperfusion
(I/R)-induced acute renal failure involve multiple signal
transduction cascade systems. Endothelial dysfunction has
a major role in the development of renal injury because
cytokines and chemokines, released from endothelial cells,
potentiate endothelial interactions with leukocytes and
platelets, and weaken microcirculation and the recovery
process.1,2 In addition, injury to endothelial cells leads to cell
swelling and a debilitated endothelial barrier. The synthesis of
cytokines, such as tumor necrotic factor-a (TNF-a), is an
early event which occurs after 30 min of ischemia.3 TNF-a
upregulates adhesion molecules such as E-selectin, P-selectin,
intercellular adhesion molecule-1 (ICAM-1), and vascular
cell adhesion molecule (VCAM-1), and chemokines, such as
the macrophage inflammatory protein 2 and monocyte
chemoattractant protein 1.4–7 These molecules trigger the
infiltration of inflammatory cells into the tubulointerstitium.
Leukocyte adhesion to endothelial cells promotes dynamic
cross-talk between the two cell types that facilitates further
leukocyte infiltration and activation, free radical generation,
production of proinflammatory mediators, and tubulointer-
stitial damage.8
Sphingosine 1-phospate (S1P) is a physiological mediator
that affects multiple biological systems including prolifera-
tion, cytoskeletal organization, differentiation, and cell
motility.9 These cellular responses are mediated through
various high-affinity S1P receptors. Five S1P receptors
(S1P1–5) encoded by the endothelial differentiation gene
(EDG) family have been described.10,11 The S1P1 receptor is
widely expressed in the body including the kidney.11 Besides
expression in the endothelial cells, this receptor is present in a
variety of immune cells including T cells, B cells, macro-
phages, and dendritic cells.12 The S1P1 receptor plays an
important role in maintaining endothelial cell integrity,13,14
and trafficking of lymphocytes.12
SEW2871, an S1P1-selective agonist, is structurally
unrelated to S1P and is not phosphorylated upon binding
to the S1P1 receptor. Although less potent than S1P, it
induces responses equivalent to 100% of those seen with S1P
in guanosine 50-3-o-(thio) triphosphate binding, calcium
flux, kinase activation, and cell migration.15 SEW2871 is not
active on S1P25 receptors and unlike FTY720, a non-
selective S1P receptor agonist,16 does not cause bradycardia,
which is mediated via the S1P3 receptor.
15 In addition, S1P2
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receptor has been shown to mediate S1P-induced coronary
artery smooth muscle contraction.17 Consequently, an S1P1-
selective agonist in theory may have advantages over non-
selective S1P receptor agonists. Recently, Jo et al.18 have
further characterized the receptor binding and signaling of
SEW2871 and shown that both SEW2871 and natural ligand
S1P induce S1P1 internalization and recycling, in contrast to
FTY720-phosphate, which induces receptor degradation.
Because of its selectivity, we tested the effects of SEW2871
on I/R-induced renal injury in a mouse model.
RESULTS
SEW2871 improved renal function and histopathology
after I/R injury
To study the effects of SEW2871 on I/R injury in the kidney,
we used a mouse model with transient bilateral clamping of
the renal pedicles. At 24 h after ischemia, the mice showed
a marked deterioration in renal function, while the mice
that received SEW2871 showed significant improvement
(Figure 1. Plasma creatinine level: I/R only: 1.4470.12 vs
I/Rþ SEW2871: 0.8670.12 mg/dl, Po0.01). The findings
in renal function were consistent with the results of the
histology examination. The mice received SEW2871 treat-
ment without I/R did not show any significant tubular
damage or neutrophil infiltration (Figure 2a). I/R caused
severe tubular damage including tubular necrosis, tubular
dilatation, and cast formation. The dilated tubules were lined
by flattened epithelial cells and in some areas there were
patchy loss of tubular cells with cell debris in the lumen
(Figure 2b). Pretreatment of SEW2871 reduced the I/R
induced tubular damage significantly (Figure 2c, see Figure
S1 for color figures) and retained lower acute tubular necrosis
scores (Figure 3a, I/R only: 4.370.2 vs I/Rþ SEW2871:
2.570.4, n¼ 6, Po0.05). The I/R injury resulted in an
increase of neutrophils in outer medullary area, but
SEW2871 markedly reduced neutrophil infiltration (Figure
3b, neutrophils per high power field: I/R only: 16.972.2 vs
I/Rþ SEW2871: 3.970.9, n¼ 6, Po0.01). Similar reduction
was observed in macrophage infiltration as shown in Figure 4.
The macrophages were labeled with anti-F4/80 antibodies,
monoclonal antibodies specifically against the mature mouse
macrophage.19 In the non-ischemic kidneys, whether treated
with SEW2871 or not (Figure 4a), a few anti-F4/80-labeled
cells were found throughout the kidney with the highest
number in the medullary interstitial areas, representing
resident macrophages.20 After I/R injury, the F4/80-positive
cells increased markedly (Figure 4b). SEW2871 treatment
(Figure 4c) significantly reduced the number of macrophages
(Figure 3b, F4/80-positive cells per high-power field: I/R only
3573 vs I/Rþ SEW2871: 1272, n¼ 6, Po0.01). In contrast,
there were very few T cells stained with anti-CD4 antibodies
in kidney sections after I/R injury (Figure 4d, see Figure S2
for color figures). This is consistent with previous report that
only a small infiltration of CD4þ T cells was observed 24 h
after I/R injury.21,22 There were no differences in the number
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Figure 1 | Mouse plasma creatinine (Cr) levels of control (closed
bars), SEW2871 treatment only (gray bars); I/R injury (open bars),
and I/Rþ SEW2871 treatment (striped bar). Values are means7s.e.
I/R injury increased plasma Cr level after 24 h (##Po0.01 vs control,
n¼ 6) and SEW2871 significantly reduced this elevation (**Po0.01 vs
I/R, n¼ 6).
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Figure 2 | Histology examination of the kidney (hematoxylin and
eosin stain, original magnification:  400). (a) SEW2871 treatment
per se without I/R injury did not cause significant injury or leukocyte
accumulation in the kidney. (b) There was severe tubular damage
with neutrophil infiltration (white arrow) in the kidney 24 h after I/R
injury, (c) while SEW2871-treated kidney showed a significant
reduction in I/R-induced tubular damage and neutrophil infiltration.
(See Figure S1 for color pictures.)
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Figure 3 | Effects of SEW2871 on acute tubular necrosis scores
and infiltration of neutrophils and macrophages. Pretreatment
with (a) SEW2871 reduced acute tubular necrosis scores and (b)
infiltrating neutrophils and macrophages 24 h after I/R injury. HPF:
high-powered field. n¼ 6 per group, **Po0.01 vs I/R.
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of CD4þ T cells between the kidneys from I/R injury and
I/R injury plus SEW2871 treatment. The renal function
improved 4 days after ischemia in both groups (data not
shown). The administration of SEW2871, up to 40 mg/kg
body weight via gavage for 4 days, was well tolerated.
SEW2871 lowered the circulating leukocyte count in mice
subjected to I/R injury
The SEW2871 treatment is known to reduce circulating
lymphocytes in normal mice.15 We demonstrated that
SEW2871 also effectively lowered the circulating leukocyte
count by 37% in mice subjected to an I/R injury (Po0.05,
Table 1). This decrease was mainly due to a decrease in the
lymphocyte count (69% reduction, Po0.01, Table 1). Inter-
estingly, the eosinophil count was also reduced by SEW2871
(Po0.05, Table 1), a finding which has not been reported
previously. The significance of lower eosinophil count in
renal I/R injury is currently unclear.
SEW2871 reduced TNF-a and adhesion molecules
Ischemia and reperfusion injury in the kidney induces a surge
in tissue levels of TNF-a and adhesion molecules that include
P-selectin, E-selectin, ICAM-1, and VCAM-1.1,3,23 In our
study, 24 h after I/R, the mRNA abundance of all five
molecules except VCAM-1 increased significantly (3.5-, 4.1-,
3.5-, 4.8-folds for TNF-a, P-selectin, E-selectin, ICAM-1,
respectively, all Po0.05 except Po0.01 for ICAM-1,
Figure 5). I/R renal injury increased mRNA abundance of
VCAM-1 by 65%, but the difference was not statistically
significant (P¼ 0.06, Figure 5). The administration of
SEW2871 suppressed the I/R-induced elevation of TNF-a,
P-selectin, and ICAM-1 mRNA abundance by 47, 59, and
54%, respectively (all Po0.05), but did not affect the gene
expression of E-selectin and VCAM-1 (Figure 5).
To test whether SEW2871 itself has any effects on the
baseline gene expression of TNF-a and adhesion molecules,
we administered SEW2871 to a group of mice that was not
subjected to the I/R procedure. SEW2871 suppressed TNF-a,
P-selectin, and ICAM-1 modestly (38, 31, 23% reduction vs
vehicle control, respectively, all Po0.05), but had no effects
on E-selectin and VCAM-1 (Figure 5).
Reduction or absence of ICAM-1 has been shown to
protect against renal I/R injury.23 We further examined
whether SEW2871 also affected ICAM-1 protein expression
after I/R injury using immunofluorescent staining. ICAM-1
immunoreactivity was minimal in the kidney without
ischemia (Figure 6a), but markedly increased 24 h after I/R.
It was strongest in the peritubular capillaries of the outer
medulla (Figure 6b, see Figure S3 for color figures) and was
colocalized with von Willebrand factor indicating that
ICAM-1 was mainly expressed in the endothelial cells (See
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Figure 4 | SEW2871 reduces infiltrating macrophages in ischemic
kidneys. (a–c) Immunofluorescent staining (red) of macrophages and
(d) CD4þ T cells using anti-F4/80 and anti-CD4 antibodies,
respectively (original magnification:  400). (a) There were resident
macrophages in untreated kidney. (b) Macrophages increased
markedly 24 h after I/R injury and (c) pretreatment with SEW2871
reduced the number of macrophages. (d) CD4þ T cells (one in the
middle) were rarely seen in the kidney 24 h after I/R injury.
(See Figure S2 for color pictures.)
Table 1 | Total and differential leukocyte count from peripheral blood ( 1000 cells/ll)
WBC NE LY MO EO BA
I/R+SEW 4.5370.94* 3.6470.16 0.6370.07** 0.1170.04 0.0870.01* 0.0670.04
I/R only 7.2070.93 4.8470.82 2.0170.25 0.2470.07 0.2670.08 0.0870.03
Normal range 1.80–10.70 0.10–2.40 0.90–9.30 0.00–0.40 0.00–0.20 0.00–0.20
BA: basophil; EO: eosinophil; I/R: ischemia and reperfusion; LY: lymphocyte; MO: monocyte; NE: neutrophil; SEW: SEW2871; WBC: white blood cell.
**Po0.01, *Po0.05 vs I/R only.
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Figure 5 | Effects of SEW2871 on mRNA abundance on TNF-a and
adhesion molecules. Renal mRNA abundance of TNF-a, P-selectin, E-
selectin, ICAM-1, and VCAM-1 in mice with I/R injury (open bars), I/R
and SEW2871 treatment (3rd bar), SEW2871 treatment only (gray
bars), and without treatment (closed bars). mRNA levels are
expressed as percent relative to a baseline of 100% and normalized
with dynactin mRNA. N¼ 6–8, *Po0.05, and **Po0.01, vs control;
#Po0.05 and ##Po0.01 vs I/R.
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Figure S4). Treatment with SEW2871 led to a significant
reduction in ICAM-1 immunoreactivity (Figure 6c).
The results of P-selectin immunofluorescence studies were
similar to those of ICAM-1. In the untreated kidney, the
P-selectin immunoreactivity was minimal (Figure 7a). I/R
injury markedly increased P-selectin immunoreactivity
(Figure 7b). The P-selectin was mainly expressed in the
endothelial cells of peritubular capillaries as shown by double
staining using antibodies against von Willebrand factor
(Figure 7d). Pretreatment of SEW2871 reduced the P-selectin
immunoreactivity significantly (Figure 7c).
To confirm the mRNA finding of TNF-a, we performed
immunofluorescent staining using anti-TNF-a antibodies.
The immunoreactivity of TNF-a was minimal in the
untreated kidney (Figure 8a). We observed marked increase
of TNF-a immunoreactivity (staining red) in the tubular cells
after I/R injury (Figure 8b) and the increase was reduced by
SEW2871 treatment (Figure 8c). To verify the location of
TNF-a, we did double staining with anti-TNF-a antibodies
(red) and anti-Tamm–Horsfall protein (THP) (green), a
marker for the thick ascending limb of the Henle’s loop, and
found that TNF-a immunoreactivity did not overlap with
THP positive cells, suggesting that TNF-a immunoreactivity
is mainly present in the proximal tubule.
DISCUSSION
The importance of the inflammatory cascades triggered by
endothelial cells during I/R injury has been well established.
We demonstrated here for the first time that the S1P1-
selective agonist, SEW2871, protects against I/R-induced
renal injury in a mouse model. SEW2871 blocked the I/R-
induced upregulation of gene expression of TNF-a, ICAM-1,
and P-selectin in the kidney, reduced tubular necrosis, and
reserved renal function. In our short termed study, SEW2871
is apparently well tolerated.
In this study, we treated mice with SEW2871 at the dosage
which has been well studied by Sanna et al.15 After oral
administration of SEW2871 (20 mg/kg), the plasma concen-
tration of SEW2871 reached to 10–12 mM at 5 h, and
subsequently decreased to 8 mM at 12 h, and 2 mM at 24 h.
The plasma concentrations of SEW2871 correlate well with
peripheral lymphocyte counts. This treatment maintains the
maximal suppression of circulating lymphocytes for 12 h. In
our study, we have reproduced similar lymphocytopenic
effects as Sanna et al.15 and observed a significant
renoprotective effects with this treatment.
The renoprotective effects observed in our study are
similar to those reported in knockout mice lacking CD4þ T
cells21 or both CD4þ and CD8þ T cells.24 Earlier, Takada
et al.25 reported that the blockade of T-cell CD28-B7 co-
stimulation with a recombinant fusion protein, CTLA.4Ig,
resulted in the protection against cold ischemic renal injury.
This treatment was associated with reduction in infiltration
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Figure 6 | SEW2871 reduces I/R induced ICAM expression.
(a) Immunofluorescent staining of ICAM-1 in the kidney shows
minimal immunoreactivity in baseline kidney, (b) markedly increased
immunoreactivity in peritubular capillary 24 h after I/R injury, (c) and
attenuation of immunoreactivity by SEW2871 treatment. Original
magnification:  400. Bar¼ 0.05 mm. (See Figure S3 for color
pictures.)
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Figure 7 | SEW2871 reduces I/R induced P-selectin expression.
(a) Immunofluorescent staining of P-selectin (red) shows minimal
immunoreactivity in baseline kidney, (b) increased immunoreactivity
in peritubular capillary 24 h after I/R injury, (c) and attenuation of
immunoreactivity by SEW2871 treatment. (d) The P-selectin (red) was
mainly expressed in the endothelial cells of peritubular capillaries as
shown by double staining using antibodies against von Willebrand
factor (green). Original magnification:  400.
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and activation of T cells and macrophages. The post-ischemic
renal expression of many cytokines, including TNF-a, was
significantly reduced in CTLA4Ig-treated animals. In this
study, we also observed a marked reduction in circulating
lymphocytes and the suppression of TNF-a mRNA abun-
dance in SEW2871-treated mice after I/R. It is possible that
the immunomodulatory effect of SEW2871, the inhibition of
lymphocyte egress and the subsequent infiltration in ischemic
tissues, may have a major role in its renoprotective ability.
However, we detected very few CD4þ T cells in the kidney
after I/R injury, and no effects of SEW2871 on the number of
T cells after injury. The lack of significant T-cell infiltration
24 h after I/R injury has been reported previously.21,25 It has
been suggested that an early, transient increase in T cells, a
‘hit-and-run’ hypothesis, might explain how T cells could still
have a role without clear histologic evidence of their presence
in the kidney after ischemia.22 Since, TNF-a synthesis is an
early event of ischemic injury,3 SEW2871 is likely to intervene
in the early process of I/R injury. Our data shows that
SEW2871 has a modest inhibitory effect on TNF-a mRNA
expression in baseline non-ischemic kidneys. We speculate
that this may be related to the decrease of circulating
lymphocytes, but cannot rule out the direct inhibitory effect
of SEW2871 on TNF-a synthesis.
The role of TNF-a in the development of I/R renal injury
has been well established.3,26 Infusion of a TNF-a-binding
protein decreased TNF-a bioactivity and preserved renal
function in an I/R mouse model.26 SEW2871 treatment
blocks the upregulation of TNF-a, P-selectin, and ICAM-1,
but not E-selectin and VCAM-1. The differential effects
among those adhesion molecules are quite unique. It is likely
that SEW2871 may suppress I/R-induced ICAM-1 and
P-selectin indirectly via its suppression of TNF-a, because
the addition of S1P to TNF-a-stimulated cultured endothelial
cells does not modify ICAM-1 expression.27 It is also possible
that SEW2871 may suppress ICAM-1 independent of TNF-a,
since ICAM-1 can be upregulated in TNF-a receptor 1
knockout mice.28 Our immunofluorescent staining studies
indicate that after I/R injury, TNF-a is mainly expressed in
tubular cells, while ICAM-1 and P-selectin are expressed in
endothelial cells, findings that are consistent with previous
studies.29,30 The increased expression of these proteins was
suppressed by SEW2871 treatment. These findings suggest
that there are cross-talks among tubular, endothelial, and
inflammatory cells during renal I/R injury, and that the
renoprotective mechanisms of SEW2871 are likely to be
complicated. Furthermore, we could not exclude that
SEW2871 may have hemodynamic effects on the kidney.
Clearly, further studies are needed to elucidate the role of
S1P1 receptors in renal responses to I/R injury.
S1P mediates the induction of E-selectin and VCAM-1 by
TNF-a.31 In fact, S1P itself also stimulates both E-selectin and
VCAM-1, independent of TNF-a, in cultured endothelial
cells. Stable silencing of S1P1 receptor in endothelial cells
abolishes the stimulation of E-selectin induced by both TNF-
a and lipopolysaccharide.14 The S1P1 silencing only partially
suppressed ICAM-1 upregulation induced by TNF-a,
and had no effects on lipopolysaccharide-induced ICAM-1
expression. The differential effects of S1P on ICAM-1 and
VCAM-1 were further demonstrated by Chen et al.32 When
the S1P kinase-1, the key S1P synthesis enzyme, was silenced
in endothelial cells, only VCAM-1 (not ICAM-1) expression
induced by TNF-a was affected.32 Combining these findings,
the lack of suppression of E-selectin and VCAM-1 by
SEW2871 after I/R injury, is probably due to the drug’s dual
effects on the inflammatory process: its direct stimulation of
E-selectin and VCAM-1 offsets its indirect inhibitory effects
from the suppression of TNF-a.
Regardless of the mechanisms, the decreased ICAM-1 and
P-selectin mRNA abundance and ICAM immunoreactivity
are likely to contribute to the renoprotective effects of
SEW2871. This agent is well tolerated as all the treated
animals survived on day 4 and their blood urea nitrogen
levels decreased to normal ranges. Okusa et al.30 showed a
similar reduction of ICAM-1 and P-selectin expression by A2A
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Figure 8 | SEW2871 reduces I/R induced TNF-a expression.
Immunofluorescent staining of TNF-a (red) and THP specific for the
thick ascending limb, staining green. (a) There was minimal TNF-a
immunoreactivity in untreated kidney. (b) After I/R injury, TNF-a
immunoreactivity was markedly increased in the tubular epithelial
cells without overlap with THP immunoreactivity. (c) SEW2871
treatment decreased TNF-a immunoreactivity significantly. (b, c)
Neither I/R injury nor SEW2871 treatment had effects on THP
immunoreactivity. Original magnification:  400.
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adenosine receptor agonist, DWH-146e, which also resulted in
renoprotection and the reduction of neutrophil infiltration.
Furthermore, a non-selective S1P agonist, FTY720, has been
shown to ameliorate I/R injury in rat kidneys33 and in rat renal
transplant models.34 The renoprotective effect of FTY720 was
similar to that of administrating ICAM-1 antisense oligo-
nucleotide in syngeneic renal transplants and there was little
additive effect when the two treatments were used in
combination.35 Whether the renoprotective effects of FTY720
and SEW2871 are due to inhibition of lymphocyte homing,
maintenance of endothelial integrity, or effects on renal vascular
blood flow, remains to be investigated. Future studies using
knockout mice with depletion of CD4þ T cells or both CD4þ
and CD8þ T cells will be helpful to delineate the mechanisms
of S1P1 agonists mediated renoprotection in I/R injury.
The limitation of our study is that SEW2871 was given
prior to the ischemic event because parenteral preparation of
SEW2871 is not currently available. Although this limitation
may reduce the usage of SEW2871 since most cases of acute
tubular necrosis are diagnosed after ischemic event, it is still
useful as a preventive reagent for I/R injury in the scheduled
events, such as abdominal vascular surgery and kidney
transplantation. With its immunomodulatory effects,
SEW2871 would be particularly useful in preventing both
delayed graft function and acute rejection of kidney
transplants. Furthermore, SEW2871 is the first S1P1-selective
agonist with relatively low potency. It is likely that second
generation of this class of drugs will be developed to
overcome these limitations and broaden the clinical applica-
tions. After we submitted our report for publication, we were
aware of a study performed by Okusa’s group demonstrating
similar renoprotective effects by SEW2871 and FTY720. The
renoprotective effects of FTY720 were reversed by VPC44116,
a selective S1P1 receptor antagonist, indicating that the
renoprotective effect is mediated by the S1P1 receptor.
36
In conclusion, we have demonstrated that a S1P1-selective
agonist ameliorates renal I/R injury. The renoprotective effect
is associated with the reduction of circulating lymphocytes
and suppression of pro-inflammatory genes TNF-a, ICAM-1,
and P-selectin. This observation is important because
SEW2871 is both immunomodulatory and renoprotective,
and could potentially be used for preventing I/R-induced
acute renal failure during kidney transplantation or other
abdominal vascular surgeries.
MATERIALS AND METHODS
Animals and procedures
Male NIH Swiss mice (20–25 g) were purchased from the National
Cancer Institute and allowed free access to water and standard mouse
chow. All the procedures involving animals were approved by the
animal care committee of the University of Arizona and adhering to
the NIH Guide for the Care and Use of Laboratory Animals.
The mice were divided into four groups: (1) the treatment group
received SEW2871 through a gavage 3 h before and 9 h after renal
ischemia (20 mg/kg, each). Six mice were killed 24 h after ischemia
and 4 mice continued to receive SEW2871 (40 mg/kg daily) until day
4 when they were killed. Blood samples were collected for blood
chemistry and blood cell counts with differentiation. Both kidneys
were harvested for total RNA isolation, hematoxylin and eosin
staining for histopathological scoring, and immunohistochemistry
studies; (2) the I/R group went through the same procedures as
group 1 except that they were given a vehicle instead of SEW2871
treatment; (3 and 4) the third and fourth groups received similar
SEW2871 or vehicle treatment as groups 1 and 2, respectively,
without undergoing I/R procedures.
Reagents and dosage
SEW2871 (Calbiochem, San Diego, CA, USA) was dissolved in 100%
dimethyl sulfoxide, and diluted with 50% Tween 20 as described
previously.15 SEW2871 was given orally because of its low solubility in
aqueous solution. The dosage of 20 mg/kg was selected based on the
previous study showing a consistent lymphocytopenia up to 12 h.15
Ischemia and reperfusion procedures
The mice were anesthetized with an intraperitoneal injection of
ketamine (100 mg/kg body weight) and xylazine (5 mg/kg body
weight). After a midline abdominal incision, bilateral renal pedicles
were clamped using a nontraumatic microvascular clamp (Roboz
Surgical Instruments, Gaithersburg, MD, USA) and 1 ml of 0.9%
NaCl (371C) was administered intraperitoneally. The mouse was
kept on a warm-heating pad to maintain body temperature. After
30 min ischemia, the clamps were released and the recovery of blood
flow was inspected under the microscope. Subsequently, the incision
was closed and mice were allowed to recover.
Blood chemistry and white blood cell counts
Plasma creatinine levels were measured based on the Jaffe reaction
with modification.37 White blood cell counts with differentiation
were performed by the Pathology Services at University of Arizona
Animal Care using the HEMAVET 850 Multispecies Hematology
Analyzer (Drew scientific Inc., Oxford, CT, USA).
Histopathology examination
Paraformaldehyde-fixed (4%) and paraffin-embedded kidneys were
section at 4 mM and stained with hematoxylin–eosin using standard
methods. Histological examinations were performed in a blinded
fashion. Histological changes due to tubular necrosis were
quantitated by counting the percent of tubules that displayed cell
necrosis, loss of brush border, cast formation, and tubule dilatation
as follows: 0¼ none; 1¼o10; 2¼ 11–25; 3¼ 26–45; 4¼ 46–75; and
5X76%.38 At least 10 fields (original magnification  100) were
reviewed in each slide. Neutrophil infiltration was quantitatively
assessed by counting the number of neutrophils per high-power field
at original magnification  400. Ten fields were counted in the outer
medulla on hematoxylin and eosin-stained slides.
Immunofluorescent staining
The sources and dilution of the primary and secondary antibodies
are: goat anti-mouse ICAM1 (1:100 dilution, R&D Systems Inc.,
Minneapolis, MN, USA), goat anti-mouse P-selectin and goat
anti-mouse TNF-a (both 1:100 dilution, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA), rabbit anti-human Factor VIII-related
antigen (von Willebrand factor, 1:100 dilution, Invitrogen, Carlsbad,
CA, USA), rabbit anti-human THP (1:200 dilution, Biomedical
Technologies Inc., Stoughton, MA, USA), rat anti-mouse CD4 (1:100
dilution, Biolegend, San Diego, CA, USA), Rat anti-mouse F4/80
antigen (1:400 dilution, Serotec, Raleigh, NC, USA), Alexa Flour 488
rabbit anti-goat immunoglobulin G (Hþ L) conjugate, Alexa Flour
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488 goat anti-rabbit immunoglobulin G (Hþ L) conjugate, Alexa
Flour 594 rabbit anti-rat immunoglobulin G (Hþ L) conjugate,
Alexa Flour 594 donkey anti-goat immunoglobulin G (Hþ L)
conjugate (all 1:200 dilution, Molecular Probes Inc., Eugene, OR,
USA). Immunofluorescent staining was carried out as described
previously.39 Briefly, frozen kidney samples embedded in 22-
oxacalcitriol embedding medium (Tissue-Tek, Sakura Finetechnical
Co., Torrance, CA, USA), were cut into 5 mm sections in a cryostat,
fixed with 4% paraformaldehyde for 15 min, and incubated
with primary antibodies for 1 h, then with Alexa Fluor-conjugated
secondary antibodies for 30 min, all at room temperature.
The sections were counterstained with 0.25 hematoxylin (1.5 g/l,
Sigma-Aldrich, St Louis, MO, USA) for 2 min, and mounted with
Vectashield Hard Set mounting medium (Vector Laboratories Inc.,
Burlingame, CA, USA). Images were captured by a Coolsnap digital
camera (RS Photometrics, Tucson, AZ, USA) attached to a Nikon
E600 fluorescence microscopy.
Quantitative real-time reverse transcriptase-polymerase
chain reaction
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), and first-strand cDNA was synthesized using the iScript
cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA)
according to the manufacturer’s protocols. The gene expression
profiles of inflammation-associated cytokines and adhesion mole-
cules were assessed by quantitative real-time reverse transcriptase-
polymerase chain reaction as described previously.39 The sequences
of the primers were listed in Table 2. The first-strand cDNA was
subjected to real-time polymerase chain reaction using the Cepheid
Smart Cycle II System (Cepheid, Sunnyvale, CA, USA) and the
fluorescent dye SYBR Green (Bio-Rad Laboratories, Hercules, CA,
USA) as a tracer. We used dynactin 6 as an internal standard for the
real-time analysis as its expression was constitent and unchanged
between the treatment and control groups (data not shown). Other
investigators have also found that while commonly used house-
keeping genes such as b-actin and glyceraldehyde-3-phosphate
dehydrogenase were differentially expressed, dynactin on the
other hand was unchanged on the microarray data.40 For a given
target gene, the relative gene expression was determined as
2ðstandard gene Cttarget gene CtÞ, where Ct was the first cycle at which the
reporter signal significantly exceeded the baseline signal. Melting
curve analysis was carried out at the end of a 40-cycle amplification
to validate the size of the polymerase chain reaction products.
Statistical analysis
Non-normally distributed data were analyzed by the nonparametric
unpaired Mann–Whitney test. Multiple group comparisons were
performed using analysis of variance with post-test according to
Bonferroni. P-values of o0.05 were considered statistically sig-
nificant. Values are expressed as means7s.e.
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SUPPLEMENTARY MATERIAL
Figure S1. (a) Histology examination of the kidney (hematoxylin and
eosin stain, original magnification:  400). SEW2871 treatment per se
without ischemia and reperfusion (I/R) injury did not cause significant
injury or leukocyte accumulation in the kidney. (b) There was severe
tubular damage with neutrophil infiltration (white arrow) in the
kidney 24 h after I/R injury, (c) while SEW2871-treated kidney showed
a significant reduction in I/R-induced tubular damage and neutrophil
infiltration.
Figure S2. (a–c) Immunofluorescent staining (red) of macrophages
and (d) CD4þ T cells using anti-F4/80 and anti-CD4 antibodies,
respectively (original magnification:  400). (a) There were resident
macrophages in untreated kidney. (b) Macrophages increased
markedly 24 h after ischemia–reperfusion (I/R) injury and (c) pretreat-
ment with SEW2871 reduced the number of macrophages. (d) CD4þ
T cells (one in the middle) were rarely seen in the kidney 24 h after
I/R injury.
Figure S3. (a) Immunofluorescent staining of intercellular adhesion
molecule-1 (ICAM-1) in the kidney shows minimal immunoreactivity
in baseline kidney, (b) markedly increased immunoreactivity in
peritubular capillary 24 h after ischemia and reperfusion injury, and
(c) attenuation of immunoreactivity by SEW2871 treatment. Original
magnification:  400, bar¼ 0.05 mm.
Figure S4. (a, red) Double staining of ICAM-1 and (b, green) von
Willebrand factor of kidney 24 h after ischemia and reperfusion injury
shows that ICAM-1 expresses in the (c, superimposed picture)
endothelial cells of peritubular capillaries . Original magnification:
 400.
REFERENCES
1. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology
of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199–2210.
2. Lien YH, Lai LW, Silva AL. Pathogenesis of renal ischemia/reperfusion
injury: lessons from knockout mice. Life Sci 2003; 74: 543–552.
3. Donnahoo KK, Meldrum DR, Shenkar R et al. Early renal ischemia, with or
without reperfusion, activates NFkappaB and increases TNF-alpha
bioactivity in the kidney. J Urol 2000; 163: 1328–1332.
4. Adler S, Brady HR. Cell adhesion molecules and the glomerulopathies. Am
J Med 1999; 107: 371–386.
5. Ishibashi N, Weisbrot-Lefkowitz M, Reuhl K et al. Modulation of
chemokine expression during ischemia/reperfusion in transgenic mice
overproducing human glutathione peroxidases. J Immunol 1999; 163:
5666–5677.
6. Luster AD. Chemokines – chemotactic cytokines that mediate
inflammation. N Engl J Med 1998; 338: 436–445.
7. Springer TA. Adhesion receptors of the immune system. Nature 1990;
346: 425–434.
8. Singbartl K, Ley K. Leukocyte recruitment and acute renal failure. J Mol
Med 2004; 82: 91–101.
9. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling
lipid. Nat Rev Mol Cell Biol 2003; 4: 397–407.
10. Hla T, Lee MJ, Ancellin N et al. Lysophospholipids – receptor revelations.
Science 2001; 294: 1875–1878.
Table 2 | Primers list for real-time PCR
Genes Forward Reverse Product size (bp)
Dynactin 6 TTGAAGCCATCCCTGAGAAC GTTGAGCTGCCTTTCATCGT 157
TNFa GAACTGGCAGAAGAGGCACT GGTCTGGGCCATAGAACTGA 201
P-selectin GGGCTCAACTCATCTGGTTC CATTGAGGTGAGCGATTTCA 183
E-selectin GTCTAGCGCCTGGATGAAAG ATCGCCACCAGATGTGTGTA 183
ICAM-1 AGCACCTCCCCACCTACTTT AGCTTGCACGACCCTTCTAA 160
VCAM-1 CCAAATCCACGCTTGTGTTGA GGAATGAGTAGACCTCCACCT 120
ICAM-1: intercellular adhesion molecule 1; TNF-a: tumor necrosis factor-a; VCAM-1: vascular cell adhesion molecule-1.
Kidney International (2006) 69, 1601–1608 1607
Y-HH Lien et al.: S1P1 agonist and ischemic ARF o r i g i n a l a r t i c l e
11. Kluk MJ, Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-
family of G-protein-coupled receptors. Biochim Biophys Acta 2002;
1582: 72–80.
12. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an
autocrine and paracrine network. Nat Rev Immunol 2005; 5: 560–570.
13. Lee MJ, Thangada S, Claffey KP et al. Vascular endothelial cell adherens
junction assembly and morphogenesis induced by sphingosine-1-
phosphate. Cell 1999; 99: 301–312.
14. Krump-Konvalinkova V, Yasuda S, Rubic T et al. Stable knock-down of the
sphingosine 1-phosphate receptor S1P1 influences multiple functions of
human endothelial cells. Arterioscler Thromb Vasc Biol 2005; 25: 546–552.
15. Sanna MG, Liao J, Jo E et al. Sphingosine 1-phosphate (S1P) receptor
subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation
and heart rate. J Biol Chem 2004; 279: 13839–13848.
16. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate
receptor-1 in the control of lymphocyte egress and endothelial barrier
function. Am J Transplant 2004; 4: 1019–1025.
17. Ohmori T, Yatomi Y, Osada M et al. Sphingosine 1-phosphate induces
contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc
Res 2003; 58: 170–177.
18. Jo E, Sanna MG, Gonzalez-Cabrera PJ et al. S1P1-selective in vivo-active
agonists from high-throughput screening: off-the-shelf chemical
probes of receptor interactions, signaling, and fate. Chem Biol 2005;
12: 703–715.
19. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically
against the mouse macrophage. Eur J Immunol 1981; 11: 805–815.
20. Hume DA, Robinson AP, MacPherson GG et al. The mononuclear
phagocyte system of the mouse defined by immunohistochemical
localization of antigen F4/80. Relationship between macrophages,
Langerhans cells, reticular cells, and dendritic cells in lymphoid and
hematopoietic organs. J Exp Med 1983; 158: 1522–1536.
21. Burne MJ, Daniels F, El Ghandour A et al. Identification of the CD4(+) T cell
as a major pathogenic factor in ischemic acute renal failure. J Clin Invest
2001; 108: 1283–1290.
22. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure.
Kidney Int 2004; 66: 486–491.
23. Kelly KJ, Williams Jr WW, Colvin RB et al. Intercellular adhesion
molecule-1-deficient mice are protected against ischemic renal injury.
J Clin Invest 1996; 97: 1056–1063.
24. Rabb H, Daniels F, O’Donnell M et al. Pathophysiological role of T
lymphocytes in renal ischemia–reperfusion injury in mice. Am J Physiol
Renal Physiol 2000; 279: F525–F531.
25. Takada M, Chandraker A, Nadeau KC et al. The role of the B7
costimulatory pathway in experimental cold ischemia/reperfusion injury.
J Clin Invest 1997; 100: 1199–1203.
26. Donnahoo KK, Meng X, Ayala A et al. Early kidney TNF-alpha
expression mediates neutrophil infiltration and injury after renal
ischemia–reperfusion. Am J Physiol 1999; 277: R922–R929.
27. Bolick DT, Srinivasan S, Kim KW et al. Sphingosine-1-phosphate
prevents tumor necrosis factor-alpha-mediated monocyte adhesion to
aortic endothelium in mice. Arterioscler Thromb Vasc Biol 2005; 25:
976–981.
28. Burne MJ, Elghandour A, Haq M et al. IL-1 and TNF independent
pathways mediate ICAM-1/VCAM-1 up-regulation in ischemia reperfusion
injury. J Leukoc Biol 2001; 70: 192–198.
29. Meldrum KK, Meldrum DR, Meng X et al. TNF-alpha-dependent bilateral
renal injury is induced by unilateral renal ischemia–reperfusion. Am J
Physiol Heart Circ Physiol 2002; 282: H540–H546.
30. Okusa MD, Linden J, Huang L et al. A(2A) adenosine receptor-mediated
inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal
Physiol 2000; 279: F809–F818.
31. Xia P, Gamble JR, Rye KA et al. Tumor necrosis factor-alpha induces
adhesion molecule expression through the sphingosine kinase pathway.
Proc Natl Acad Sci USA 1998; 95: 14196–14201.
32. Chen XL, Grey JY, Thomas S et al. Sphingosine kinase-1 mediates
TNF-alpha-induced MCP-1 gene expression in endothelial cells:
upregulation by oscillatory flow. Am J Physiol Heart Circ Physiol 2004;
287: H1452–H1458.
33. Troncoso P, Ortiz M, Martinez L et al. FTY 720 prevents ischemic
reperfusion damage in rat kidneys. Transplant Proc 2001; 33: 857–859.
34. Dragun D, Bohler T, Nieminen-Kelha M et al. FTY720-induced lymphocyte
homing modulates post-transplant preservation/reperfusion injury.
Kidney Int 2004; 65: 1076–1083.
35. Ortiz AM, Troncoso P, Kahan BD. Prevention of renal ischemic reperfusion
injury using FTY 720 and ICAM-1 antisense oligonucleotides. Transplant
Proc 2003; 35: 1571–1574.
36. Awad AS, Ye H, Huang L et al. Selective sphingosine 1-phosphate 1 (S1P1)
receptor activation reduces ischemia–reperfusion injury in mouse kidney.
Am J Physiol Renal Physiol 2006, Jan 10 [E-pub ahead of print].
37. Heinegard D, Tiderstrom G. Determination of serum creatinine by a direct
colorimetric method. Clin Chim Acta 1973; 43: 305–310.
38. Melnikov VY, Ecder T, Fantuzzi G et al. Impaired IL-18 processing protects
caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest
2001; 107: 1145–1152.
39. Lee CT, Shang S, Lai LW et al. Effect of thiazide on renal gene expression
of apical calcium channels and calbindins. Am J Physiol Renal Physiol
2004; 287: F1164–F1170.
40. McReynolds MR, Taylor-Garcia KM, Greer KA et al. Renal medullary gene
expression in aquaporin-1 null mice. Am J Physiol Renal Physiol 2005; 288:
F315–F321.
1608 Kidney International (2006) 69, 1601–1608
o r i g i n a l a r t i c l e Y-HH Lien et al.: S1P1 agonist and ischemic ARF
